Nelfinavir: An update on its use in HIV infection

Drugs

Volumn 59, Issue 3, 2000, Pages 581-620

  Bardsley Elliot, Anne ^a   Plosker, Creg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; HYDROXYUREA; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC DISORDER; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SALVAGE THERAPY; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034104217     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00014     Document Type: Review

References (198)

1. 1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 1998 Apr 24; 47 (RR-5): 43-83
2. 2. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998 Jul 25; 352: 314-6
3. 3. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA 2000; 283 (3): 381-90
4. 4. British HIV Association. New BHIVA guidelines for antiretroviral treatment of HIV. Available from: URL:http://www.aidsmap/com/nam/bhiva/index.htm [Accessed 25 Aug 1999]
5. 5. Jarvis B, Faulds D. Nelfinavir: a review of its therapeutic efficacy in HIV infection. Drugs 1998 Jul; 56: 147-67
6. 6. Perry CM, Benfield P. Nelfinavir: New Drug Profile. Drugs 1997; 54 (1): 81-8
7. 7. Kaldor SW, Kalish VJ, Davies JF II, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997 Nov 21; 40: 3979-85
8. 8. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8 (2): 153-64
9. 9. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease [published erratum appears in Antimicrob Agents Chemother 1996 Jun; 40 (6): 1575]. Antimicrob Agents Chemother 1996 Feb; 40: 292-7
10. 10. Speck R, Flexner C, Yu X-F. Accumulation of gag-pol polyprotein intermediates in HIV-infected cells treated with protease inhibitors [abstract no. 184]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 779
11. 11. Patick AK, Boritzki TJ, Bloom LA. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother 1997 Oct; 41: 2159-64
12. 12. Molla A, Chernyavskiy T, Vasavanonda S, et al. Synergistic anti-HIV activity of ritonavir and other protease inhibitors in the presence of human serum [abstract/poster no. 12315]. 12th World AIDS Conference; 1998 Jun 27-Jul 3; Geneva, 76
13. 13. Vandamme A-M, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999 Mar; 57: 337-61
14. 14. Powderly WG, Tebas P. Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999 Sep; 13 Suppl. 1: S41-8
15. 15. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998 Jul 30; 12: F111-5
16. 16. Simpson DM. Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clin Infect Dis 1999 Jul; 29 (1): 19-34
17. 17. Haas DW, Spearman P, Johnson B, et al. Discordant HIV-1 RNA decay in CSF versus plasma following initiation of antiretroviral therapy: a prospective ultra-intensive CSF sampling study [abstract]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, IL, USA
18. 18. Aweeka F, Jayewardene A, Staprans S, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1999 Jan 1; 20: 39-43
19. 19. Haas DW, Clough LA, Johnson B, et al. Quantification of nelfinavir (NFV) and its active metabolite (M8) in CSF and plasma, and correlation with CSF HIV-1 RNA response [abstract no. 313]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, 313
20. 20. Zorilla C, Currier J, Clark R, et al. Cericovaginal HIV RNA in HIV-positive women on 48 weeks of dual protease inhibitor combination therapy [abstract no. 233/oral presentation]. 7th European Conference on Clinical Aspects and Treatment of HIV; 1999 Oct 23-27; Lisbon, 28
21. 21. Vernazza PI, Troiani L, Flepp M, et al. Potent antiretroviral treatment results in reduced shedding of HIV-RNA and HIV-DNA in semen (abstract no. 33606]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 28
22. 22. Zhang H, Dornadulla G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998 Dec 17; 339: 1803-9
23. 23. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997 Jun 15; 126 (12): 946-54
24. 24. Dockrell DH, Badley AD, Villacian JS, et al. The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest 1998 Jun 1; 101 (11): 2394-405
25. 25. Badley AD, Parato K, Cameron DW, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999 May; 6: 420-32
26. 26. Victorino R, Sousa A, Chaves AF, et al. Effects of triple antiretroviral therapy on the expression of Fas antigen in patients with HIV1 infection [abstract no. 31178]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 531
27. 27. Chavan SJ, Tamma SL, Kaplan M, et al. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol 1999 Oct; 1: 24-33
28. 28. Henry K, Lamarca A, Myers R, et al. The safety of Viracept® (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC [abstract no. 384]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jun 22-26; Washington, DC
29. 29. Clendeninn N, Quart B, Anderson R, et al. Analysis of long-term virologic data from the VIRACEPT (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays [abstract/poster no. 372 and oral presentation]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, 372
30. 30. Kaufmann G, Zaunders J, Cunningham P. et al. Comparison of immune reconstitution in subjects treated with HAART during primary and chronic HIV-1 infection. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30 - Feb 2, San Francisco
31. 31. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2 (7): 760-6
32. 32. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453-60
33. 33. Klabe RM, Bacheler LT, Ala PJ, et al. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 1998 Jun 16; 37: 8735-42
34. 34. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998 Oct; 42: 2637-44
35. 35. Martinez-Picado J, Savar AV, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999 May; 73 (5): 3744-52
36. 36. Haubrich R, Kemper C, Witt M, et al. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen [abstract no. 1167/oral presentation]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 493
37. 37. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998 Jun 24; 279: 1984-91
38. 38. Stevens GJ, Chen M, Grecko R, et al. Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders [abstract no. 1288]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 497
39. 39. Schmidt W, Bode H, Schulzke JD, et al. Saquinavir, nelfinavir and ritonavir but not indinavir impair the epithelial barrier function in epithelial HT-19/B6 [abstract no. 820]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 208
40. 40. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998 Jan; 101 (2): 289-94
41. 41. Lee CGL, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594-601
42. 42. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1; 19: 203-9
43. 43. Drach D, Zhao S, Drach J, et al. Subpopulutions of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992 Dec 1; 80 (11): 2729-34
44. 44. Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole, the P-glycoprotein inhibitor, on ritonavir and saquinavir plasma and cerebrospinal fluid concentrations [abstract no. 658]. 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 26-29, 1999, San Francisco: 24
45. 45. Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998 Dec; 42: 3157-62
46. 46. Quart BD, Chapman SK, Peterkin J, et al. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 -a novel HIV protease inhibitor [abstract no. LB3]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29-Feb 2; Washington, DC, 167
47. 47. Viracept (Rm) (nelfinavir mesylate): Prescribing information. Agouron Pharmaceuticals, Inc.; La Jolla. CA, USA; 1999 Nov 24
48. 48. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998 Aug; 38: 736-43
49. 49. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998 Jun; 177: 1533-40
50. 50. Pai VB, Mahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother 1999 Mar; 33: 325-39
51. 51. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999 Apr; 36: 305-7
52. 52. Zhang K, Wu E, Patick A, et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantitation by LC-MS/MS and antiviral activities [abstract no. 128]. 6th European ISSX Meeting; 1997 Jun 30-Jul 3; Gothenburg, 128
53. 53. Shetty BV, Kosa MB, Khalil DA, et al. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996 Jan; 40: 110-4
54. 54. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997 Mar; 32: 194-209
55. 55. Zhang XQ, Schooley RT, Gerber JG. The effect of increasing alpha-1 acid glycoprotein (AGP) concentration on the antiretroviral efficiency of HIV protease inhibitors (PI) [abstract no. A-42]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 13
56. 56. Lillibridge JH, Lee CA, Pithavala K, et al. The role of CYP2C19 in the formation of nelfinavir hydroxy-t-butylamide (M8): in vitro/in vivo correlation [poster #109]. 5th International ISSX Meeting; 1998 Oct 25-29; Cairns
57. 57. Merry C, Barry M, Ryan M, et al. A study of the pharmacokinetics of repetitive dosing with nelfinavir [abstract no. 831]. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 211
58. 58. Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine [editorial; comment]. AIDS 1998 Jul 9; 12: 1243-4
59. 59. Jackson KA, Rosenbaum SE, Yuen G, et al. Population pharmacokinetic analysis of Viracept (TM) (nelfinavir mesylate) in HIV-infected patients enrolled in a phase III clinical trial [abstract no. 42267]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 826
60. 60. Squires K, Riddler S, Havlir D, et al. Co-administration of indinavir (IDV) 1000mg and with escalating nelfinavir (NFV) dose in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity [abstract]. Clin Infect Dis 1998 Oct; 27: 1009
61. 61. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients [abstract no. 389]. Fourth Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC.
62. 62. Khaliq Y, Gallicano K, Sahai J, et al. Effect of nelfinavir (NFV) on short and long term plasma exposure of saquinavir in hard gel capsule (SQV-HGC) during TID and BID dosing regimens [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S28
63. 63. Sadler B, Gillotin C, Chillick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract no. 12389). 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 91
64. 64. National AIDS Treatment Advocacy Project. NATAP reports, January 1998, volume 1, number 3-4 [on line] [Accessed 1998, May 27, pages 15-16]. National AIDS Treatment Advocacy Project; 1998, May 5. Available from: URL: http://www.natap.org/reports/report3.html
65. 65. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers [poster]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
66. 66. Kerr B, Yuen G, Daniels R, et al. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism [abstract no. 429]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC, 429
67. 67. Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic (PK) interaction of nelfinavir (NFV) with half-dose rifabutin (RFB) [abstract no. B203]. Can J Infect Dis 1999 March/April; 10 Suppl. B: 21B
68. 68. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11
69. 69. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998 Jul; 26: 609-16
70. 70. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4
71. 71. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Expert Opin Invest Drug 1998; 7 (3): 413-26
72. 72. Dalmau D, Gómez I, Martinez-Lacasa X, et al. Nelfinavir (NFV)/saquinavir (SQV) plasma drug levels in two different dosage schedules: a pilot study [abstract]. Clin Microbiol Infect 1999 Mar; 5 Suppl. 3: 54
73. 73. Saah A, Riddler S, Havlir DV, et al. Co-administration of indinavir and nelfinavir: pharmacokinetics, tolerability, anti-viral activity, and preliminary viral resistance [abstract no. 22352]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 334
74. 74. Slater L, Sension M, Feinberg J, et al. Fortovase BID regimens in HIV-1 infected patients: combination with 2 nucleoside analogs or with nelfinavir plus 1 NA [poster no. 390]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 390
75. 75. Beauverie P, Taburet A-M, Dessalles M-C, et al. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS 1998 Dec 24; 12: 2510-1
76. 76. Khaliq Y, Gallicano I, Seguin K, et al. Therapeutic drug monitoring of nelfinavir in HIV patients with liver disease [abstract no. 369]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 369
77. 77. Izzedine H, Diquet B, Launay-Vacher V, et al. Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. AIDS 1999 Oct 1; 13: 1989
78. 78. Krogstad P, Kerr B, Anderson R. et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22-26; Washington, DC
79. 79. van Heesjwik RPG, Scherpbier HJ, Van Leeuwen MCA, et al. Steady-state pharmacokinetics of nelfinavir mesylate (NFV; Viracept®) in HIV-infected children [abstract no. 42274]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 828
80. 80. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999 Dec 16; 341: 1874-81
81. 81. Hayashi S, Wiznia A, Jaywardene A, et al. Nelfinavir pharmacokinetics in stable HIV positive children; the effect of weight and a comparison of BID and TID dosing [abstract no. 427]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 427
82. 82. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996 Feb 15; 334 (7): 426-31
83. 83. Staszewski S, DeMasi R, Hill AM, et al. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998; 12 (15): 1991-7
84. 84. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 Mar 26; 338 (13): 853-60
85. 85. Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodefficiency virus infection [letter]. N Engl J Med 1998; 339 (6): 405-6
86. 86. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-80
87. 87. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998 Sep 10; 12 (13): 1619-24
88. 88. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999 Sep; 13 Suppl. 1: 561-72
89. 89. Gatell J, AVANTI Study Group. AVANTI 3. A randomised, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavirin anti-retroviral naive patients: 52 week data [poster]. 4th International Congress on Drug Therapy in HIV Infection; 1998 Nov 8-12; Glasgow
90. 90. Clumeck N, AVANTI 3 Study Group. AVANTI 3: A randomised double blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in antiretroviral naive patients [abstract no. 08]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, 08
91. 91. Kerr B, Pithavala Y, Zhang M, et al. Virologic response-plasma drug concentration relationship in Phase III study of nelfinavir mesylate (Viracept Rm) [abstract no. 12304]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 73
92. 92. Petersen A, Antunes F, Arasteh KN, et al. A comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) up to 96 weeks [abstract no. 205/oral presentation]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection: 1999 Oct 23-27; Lisbon, 19
93. 93. Johnson M, Nelson M, Peters B, et al. A comparison of BTD and TID dosing of nelfinavir mesylate when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks [abstract/poster no. 1-216]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 433
94. 94. Post J, Williams C, Mulrow M, et al. An open-label randomised trial switching nelfinavir dosing from TID to BID: twelve month report [abstract/poster]. 37th Annual Meeting of the Infectious Diseases Society of America; 1999 Nov 18-21; Philadelphia
95. 95. Munsiff AV, Razaq M. Twice daily nelfinavir results in more durable suppression than TID dosing [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
96. 96. Hecht F, Smith D, Cooper D, et al. Treatment of primary HIV infection with nelfinavir, zidovudine, and lamivudine [abstract/poster no. 12197]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 50
97. 97. Albrecht M, Katzenstein D, Bosch R, et al. ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFZ) in combination with new nucleoside analogs in nucleoside experienced subjects (subj.) [abstract no. 489]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 489
98. 98. Albrecht M, Katzenstein D, Bosch R, et al. ACTG 364 -Nelfinavir (NFV) and/or Efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects (subj): week 48 ultrasensitive HIV RNA results [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
99. 99. Jemsek J, Kagan S, Martin G, et al. A phase II, open-label, multicenter study to characterize the effectiveness, safety, and pharmacokinetics of nelfinavir in combination with DMP 266 in antiretroviral therapy naive or nucleoside analogue experienced HIV-infected patients [DMP 266-024] [poster]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego
100. 100. Kagan S, Jemsek J, Martin DG, et al. Initial effectiveness and tolerability of nelfinavir (NFV) in combination with efavirenz (EFV, Sustiva, DMP 266) in antiretroviral therapy naive or nucleoside analogue experienced HIV-1 infected patients; characterization in a phase II, open-label, multi-center study at >36 weeks (Study DMP 266-024) [abstract no. 1-102]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 394
101. 101. Eyster E, Jemsek J, Kagan S, et al. Initial effectiveness and tolerability of nelfinavir in combination with efavirenz (Sustiva Rm, DMP 266) in antiretroviral therapy naïve or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II, open-label, multicenter study at 24 weeks (Study DMP 266-024) [abstract no. 22386]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 341
102. 102. Slater L, Goodgame J, Wathen L, et al. Antiviral effect of increasing nelfinavir (NFV) concentrations using delavirdine (DLV) in combination with didanosine (ddI) and stavudine (d4T) is maintained through 48 weeks of therapy [abstract no. 1989]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 523
103. 103. Gatell J, Kuritzkes D, Green S, et al. Twice daily dosing of delavirdine (DLV) in combination with nelfinavir (NFV), didanosine (ddI), and stavudine (d4T) results in significant decreases in viral burden [abstract/poster no. 1981]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 520
104. 104. Skowron G, Leoung G, Yen-Lie BB, et al. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): suppression of HIV-1 RNA to fewer than 50 copies/ml during 5 months of therapy [abstract no. 12275]. 12th World AIDS Conference 1998; Jun 28-Jul 3; Geneva, 67
105. 105. Rana KZ, Dudley MN. Human immunodeficiency virus protease inhibitors. Pharmacotherapy 1999; 19 (1): 35-59
106. 106. Johnson M, SPICE (NV 15436) Study Group. Quadruple therapy with saquinavir-soft gelatin capsules (SQV-SGC) plus nelfinavir (NFV) versus triple therapy with either SQV-SGC or NFV in patients with antiretroviral experience or high baseline viral load [poster no. 389]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 389
107. 107. Clark R, Currier JS, Greiger P, et al. Efficacy and safety of BID and TID regimens of nelfinavir (NFV) + stavudine (d4T) + lamivudine (3TC) in HIV-infected women: 48 week results of the Women First Study [poster no. 1988]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 523
108. 108. Cohen C, Mogyoros M, Sands M, et al. TIDBID study: Fortovase™ (FTV) TID regimen compared to FTV BID or FTV + NFV BID regimens in HIV-1-infected patients [abstract/poster no. 1508]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 473
109. 109. Kravcik S, Farnsworth A, Patick A, et al. Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstract no. 394c]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, 394c
110. 110. Lyle L, Strebel G. Effect of nelfinavir/indinavir/delavirdine in HIV+ patients with extensive antiviral experience [poster no. 12329]. 12th World AIDS Conference; Jun 28-Jul 3; Geneva, 79
111. 111. Gallant JE, Raines C, Sun E, et al. A phase II study of ritonavir-nelfinavir combination therapy: 48-week data [poster]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago
112. 112. Squires K, Riddler S, Havlir D, et al. Co-administration of indinavir (IDV) 1200 mg with nelfinavir (NFV) 1250 mg in a twice daily regimen: preliminary safetly, PK activity [poster no. 364]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 364
113. 113. Mellors J, Lederman M, Haas D, et al. Durable activity of ziagen (Abacavir, ABC) combined with protease inhibitors (PI) in therapy naive adults [abstract no. 625]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 625
114. 114. Eron J, Haubrich R, Richman D, et al. Safety and efficacy of amprenavir in combination with other protease inhibitors [abstract]. AIDS 1998; 12 Suppl. 4: S38
115. 115. Rawlings MK, Mayer SL, Lapins D, et al. Ritonavir confers superior HIV-RNA suppression compared to other PIs in both PI naïve and PI experienced HIV-infected patients [abstract]. AIDS 1998; 12 Suppl. 4: S32
116. 116. Easterbrook PJ, Newson R, Ives NJ, et al. Predictors of virologic response and subsequent failure to five different initial protease inhibitor (PI) treatment regimens [abstract no. 171]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 171
117. 117. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999 Feb; 13 (4): 367-73
118. 118. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999 Apr 16; 13: F35-43
119. 119. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999 Apr; 20: 299-321
120. 120. Bahrani A, Oldfield EC III. Substitution of nelfinavir (NV) for indinavir (IV) in patients on combination therapy and the effect on viral loads [abstract no. 1-241]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 440
121. 121. Trylesinski A, Dohin E, Delmas C, et al. Allieviating protease inhibitor constraints and for a viral load maintained below the limit of quantification for the long term efficacy, tolerance and compliance: the nelfinavir switch solution [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S45
122. 122. Cohen CJ, Hellinger JA, Stein AJ, et al. Ongoing experience with nelfinavir substitution for indinavir or ritonavir/ saquinavir in HIV+ suppressed below 400 copies/ml [abstract/poster no. 12332]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 79
123. 123. Wensing AMG, Reedijk M, Richter C, et al. Continued viral suppression and decrease of triglycerides and γ-GT after switch from a ritonavir-containing regimen to a nelfinavir-or a saquinavir SGC/nelfinavir-containing regimen [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
124. 124. Starrett B, Conner S. Maintenance of viral suppression and improvement of metabolic parameters after replacing ritonavir with nelfinavir in a HAART regimen [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
125. 125. Knechten H, Lippok B, Knickmann M, et al. Switch from indinavir (IDV) to nelfinavir (NFV) in patients on antiviral therapy with stavudin (d4T) and lamivudin (3TC) [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S47
126. 126. Butcher D, Greene J, Duong P, et al. Virologic response in patients switched to nelfinavir regimens after having viral RNA suppression on indinavir combination regimens [abstract]. AIDS 1998 Nov; 12 Suppl. 4: S32
127. 127. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995 Apr 6; 374: 569-71
128. 128. Lawrence J, Schapiro J, Winters M, et al. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis 1999 Jun; 179: 1356-64
129. 129. Race E, Dam E, Obry V, et al. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13: 2061-8
130. 130. Gulick RM, Katzenstein D, Hu J, et al. Salvage therapy with saquinavir soft gel capsules in combination with ritonavir or nelfinavir and delavirdine, adefovir dipivoxil, or both: ACTG 359 [abstract no. 020]. Second International Workshop on Salvage Therapy for HIV Infection; 1999 May 19-21; Toronto, 19
131. 131. Hammer S, Squires K, Degruttola V, et al. Randomised trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virologic failure receiving indinavir (IDV) [abstract no. 490]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, 490
132. 132. Chiranni A, Buccoliero G, Nacca C, et al. Salvage therapy with saquinavir (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delaverdine (DLV) and stavudine (D4T) [abstract no. 619]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 143
133. 133. Kravcik S, Victor G, Angel JB, et al. Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy. Clin Infect Dis 1999 Sep; 29: 702-3
134. 134. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor - containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999 Jun; 179: 1375-81
135. 135. Casado JL, Dronda F, Garcia-Arata I, et al. Efficacy and tolerability of the combination of nevirapine, nelfinavir and saquinavir after ritonavir or indinavir failure [abstract no. 529]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 112
136. 136. Pumarola T, Martinez E, Buira E, et al. Salvage therapy with nevirapine and nelfinavir in HIV-1 protease inhibitor-experienced patients [abstract no. 019]. Second International Workshop on Salvage Therapy for HIV Infection; 1999 May 19-21; Toronto, 19
137. 137. Sullivan A, Shaw A, Nelson M, et al. Salvage therapy using a nelfinavir-and nevirapine-containing regimen [abstract no. I-194]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 1-194
138. 138. Cassano P, De Wit S, Gerard M, et al. Viral and immune response to nelfinavir-saquinavir (NFV-SQV) or ritonavir-saquinavir (RTV-SQV), in HIV+ patients heavily pretreated with protease inhibitors [abstract no. I-247]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 442
139. 139. Maserati R, Seminari E, Pan A, et al. Efficacy of efavirenz (EFV), nelfinavir (NFV) and stavudine (d4T) rescue therapy in HIV-1 infected patients with CD4+ count <200 cell/mmc [abstract no. 698]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 168
140. 140. Arrizabalaga J, Iribarren JA, Rodríguez-Arrondo FJ, et al. Salvage therapy with ddI + hydroxyurea (HU) + efavirenz (EFV) + nelfinavir (NFV) in patients who had previously failed indinavir (IDV)/ritonavir (RIT) regimens: 24 weeks follow-up [abstract no. 2206]. 39th Interscienee Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 537
141. 141. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999 Feb 4; 13: F17-21
142. 142. Duval X, Le Moing V, Peytavin G, et al. Nelfinavir (NFV)-saquinavir (SQV)-efavirenz (EFV) association as part of antiretroviral therapy in protease inhibitor (PI) experienced HIV-infected patients (Pts) [abstract no. 2205]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 2205
143. 143. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999 Feb 4; 13: F23-8
144. 144. Zolopa A, Tebas P, Gallant J, et al. The efficacy of ritonavir (RTV)/saquinavir (SQV) antiretroviral therapy (ART) in patients who failed nelfinavir (NFV): a multicenter cohort study [abstract no. 2065]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 527
145. 145. Hall CS, Raines CP, Barnett SH, et al. Efficacy of salvage therapy containing ritonavir and saquinavir alter failure of single protease inhibitor-containing regimens. AIDS 1999; 13 (10): 1207-12
146. 146. Cavorus A, Thompson CE, Salvato PD. Salvage therapy for antiretroviral failure in HIV+ patients [abstract no. 22402]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 344
147. 147. Hawkins T, Angel C, Petersen M, et al. Successful rescue therapy in patients with multiple prior PIs and NRTIs [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
148. 148. Roca B, Gomez A, Arnedo A, et al. A randomized, comparative study of lamivudine plus stavudine with indinavir or nelfinavir, in treatment-experienced HIV-infected patients [abstract no. 594]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 482
149. 149. Delmas C, Szafir D, Trylesinski A, et al. Safety profile of Viracept in the treatment of HIV patients: the French compassionate use program experience [abstract no. 12393]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 92
150. 150. Cline P, Hall T, Lane T. Patient adherence with indinavir (IDV) and nelfinavir (NFV) determined by medication vial electronic monitoring system [abstract]. Clin Infect Dis 1998 Oct; 27: 1013
151. 151. Harwell JI, Morris A, Watson-Bitar MA. Adherence and outcomes of patients taking nelfinavir three times versus twice daily [abstract]. Clin Infect Dis 1998 Oct; 27: 1006
152. 152. Arlievsky NZ, Li KI, Munoz JL. Quadruple antiretroviral therapy combining nelfinavir and saquinavir in HIV-infected children [abstract no. 13-1-4]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 363
153. 153. Kline MW, Fletcher CV, Brundage RC, et al. Long-term pediatric study of saquinavir soft-gelatin capsules (SQV-SGC) plus nucleoside reverse transcriptase inhibitors (NRTIs) with and without nelfinavir (NFV) [abstract no. 1998]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 526
154. 154. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus I-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999 May; 28: 1109-18
155. 155. Douglas SD, Yong FH, Starr SE, et al. Flow cytometry shows immune recovery in HIV-infected children receiving efavirenz (EFV), nelfinavir (NFV) and nucleoside reverse transcriptase inhibitors (NRTIs) [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
156. 156. Funk MB, Linde R, Wintergerst U, et al. Viral load and CD4-cell count under a triple-therapy with nelfinavir and two RT-inhibitors in previously untreated HIV-infected children [abstract no. 12207]. 12th World AIDS Conference; Jun 28-Jul 3, Geneva, 63
157. 157. Mitchla Z, Sharland M, Delmas N, et al. UK experience of nelfinavir in paediatric HIV-1 infection [abstract no. 12258]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 63
158. 158. Nadal D, Steiner F. Short-term of effects of ritonavir and nelfinavir in HIV-infected children [abstract no. 12251]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 62
159. 159. Ramos JT, Fortuny C, Bertrán JM, et al. Nelfinavir (NFV) in combination with 2 reverse transcriptase inhibitors (RTI) in HIV-infected children: 12 month follow-up [abstract no. 752]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 185
160. 160. Vavro CL, Zimmermann AM, MeClernon DR, et al. Virologic response of 12 therapy-experienced children receiving 24 weeks of nelfinavir triple therapy [abstract no. I-150]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 411
161. 161. Notheis G, Hoffmann F, Wintergerst U, et al. Antiretroviral salvage-therapy with the PI-combinations RTV+SQV and NFV+SQV in children with HIV-1 infection [abstract no. 745]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 183
162. 162. Puga AM, Kronschnabel DF, Widmayer S. Twice daily nelfinavir in antiretroviral therapy experienced (ART) pediatric patients [abstract/poster]. 37th Annual Meeting of the Infectious Diseases Society of America; 1999 Nov 18-21; Philadelphia
163. 163. Rosenberg M, Dobroszycki J, Fennelly G, et al. Long term follow-up of a group of HIV-1 infected children initiating HAART early in infancy [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
164. 164. Ribeiro A, Doroana M, Tavares L, et al. Analysis of the safely profile at 48 weeks of four treatment groups with different protease inhibitors [abstract no. 594]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 594
165. 165. Bonfanti P, Faggion I, Valsecchi L, et al. Adverse reaction in patients treated with PIs: a prospective multicentre study [abstract no. 115]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon, 11
166. 166. Dretler R, Maclure K, Connor S. Antiviral activity of a BID nelfinavir-containing HAART regimen in HIV-infected, treatment-naive subjects in a clinical practice [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Fancisco
167. 167. Kosmyna JM, MacArthur RD. The incidence and severity of diarrhea in HIV+ patients from a large, urban medical center who have taken nelfinavir in the past twelve months [abstract no. 12392]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 92
168. 168. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 May 7; 12: F51-8
169. 169. Carr A, Miller J, Law M, et al. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to PI-related LD syndrome [abstract no. 11]. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 1999 Jun 26-28; San Diego, 11
170. 170. Kotler DP. Summary Report. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 1999 Jun 26-28; San Diego
171. 171. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13 (13): 1659-67
172. 172. Galli M, Ridolfo AL, Gervasoni C, et al. Incidence of fat tissue abnormalities in protease inhihitor-naive patients treated with NRTI combinations [abstract no. 20]. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 1999 Jun 26-28; San Diego, 20
173. 173. Caldwell R, Rothstein A, Allmon C, et al. Evaluation of protease inhibitor-associated hyperglycemia in a university-based HIV clinic [abstract/poster no. 12395]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 92
174. 174. Kaufman MB, Simionatto C. A review of protease inhibitor-induced hyperglycemia. Pharmacotherapy 1999 Jan; 19: 114-7
175. 175. Nelson MR, Moyle G, Newell A. The incidence of hyperlipidaemia with protease inhibitors (PI) [abstract no. I-87]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 389
176. 176. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors Circulation 1999 Aug 17; 100: 700-5
177. 177. Rothstein AM, Caldwell RD, Allmon C, et al. Investigation of protease inhibitor-associated hypercholesterolemia in a university-based HIV clinic [abstract no. I-91]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 390
178. 178. Keruly JC, Mehta S, Chaisson RE, et al. Incidence of and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor [abstract no. I-95]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 392
179. 179. Pollner J, Aronson NE, McHugh S, et al. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors [abstract no. 12269]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 66
180. 180. Dube MP, Johnson DLJ, Currier JSC, et al. Protease inhibitor-associated hyperglycemia: results of switching from indinavir to nelfinavir [abstract no. 32172]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 554
181. 181. Fleming CA, Cilento JJ, Steger KA, et al. New onset diabetes mellitus (DM) related to protease inhibitors (PI): clinical features, demographics and insulin levels. Clin Infect Dis 1998 Oct; 27: 1012
182. 182. Bouchard O, Gavazzi G, Leclercq P, et al. Onset diabetes mellitus associated with protease inhibitor therapy [abstract no. 12308]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 74
183. 183. Paterson DL, Singh N. Exacerbated hyperglycemia associated with nelfinavir. Ann Pharmacother 1998 May; 32: 609-10
184. 184. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [letter]. Ann Intern Med 1997 Nov 15; 127: 947
185. 185. Cormier K, Lewis R, Clendeninn NJ. Person-time analysis comparing rates of adverse events possibly related to increased lipids between nelfinavir and control patients in five clinical trials [abstract/poster no. 061]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 1999 Jun 26-28; San Diego, 52
186. 186. Coplan P, Cormier K, Japour A, et al. MI incidence in 4 protease clinical trial programs [abstract]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco
187. 187. Brady MT. Management of HIV-1 infection in children: special considerations. Dis Manage Health Outcomes 1998 Aug; 4: 73-91
188. 188. George S, Swindells S, Knudson R, et al. Thromboembolic disease associated with initiation of protease inhibitor therapy [abstract no. 60160]. 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, 1028
189. 189. Ladisa N, Maggi P, Perulli LM, et al. Bilateral saphenous vein thrombosis associated with a triple-drug regimen including nelfinavir (NFV) in a HIV-patient: case report. AIDS 1998 Nov; 12 Suppl. 4: S57
190. 190. Hewitt R, Hernandez F, Shelton M. Systemic hypertension associated with indinavir [abstract no. 1310]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 505
191. 191. Demoly P, Messaad D, Trylesinski A, et al. Nelfinavir-induced urticaria and successful desensitization. J Allergy Clin Immunol 1998 Nov; 102: 875-6
192. 192. Yasuoka A, Aizawa S, Fukushima S, et al. Successful desensitization of allergic reactions due to nelfinavir in patients with HIV-1 infection [abstract no. I-68]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 383
193. 193. Di Martino V, Ezenfis J, Benhamou Y, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS 1999; 13 (11): 1421-3
194. 194. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy among HIV-infected adults: the role of protease inhibitors and hepatitis C infection [abstract no. H-116]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 348
195. 195. Grunke M, Kraetsch H-G, Löw P, et al. Nelfinavir associated with peripheral neuropathy in an HIV-infected patient. Infection 1998 Jul-Aug; 26: 252
196. 196. Lorenzi P, Masserey Spicher V, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998 Dec 24; 12: F241-7
197. 197. Moyle GJ, Gazzard BG, Cooper DA. Antiretroviral therapy for HIV infection: a knowledge-based approach to drug selection and use. Drugs 1998 Mar; 55: 383-404
198. 198. Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999 Dec; 58 (6): 1165-203